What is GPCR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.50B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for GPCR?

P/E (TTM) is n/a and 52-week range is $20.73 to $94.90 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s GPCR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for GPCR?

The company profile lists net income (TTM) near -$74M, EPS (TTM) near -$1.04 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Structure Therapeutics Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in South San Francisco, California, US, 71.3M shares outstanding, ISIN US86366E1064 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Structure Therapeutics Inc.

$GPCR

Health Care · Pharmaceuticals

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California and currently employs 281 full-time employees. The company went IPO on 2023-02-03. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. The company is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. The company is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.

Employees

281

Website

structuretx.com/

IPO

2023-02-03

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US86366E1064

Headquarters

South San Francisco, California, US

Shares outstanding

71.3M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

94.59%

Browse other companiesFree AI scores and summaries for more stocks